• Explore /
  • Poster
  • / TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR gene–mutated, metastatic castration-sensitive prostate cancer (mCSPC).

TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR gene–mutated, metastatic castration-sensitive prostate cancer (mCSPC).

Abstract Video & Slides Poster

Authors

Neeraj Agarwal

Neeraj Agarwal

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Neeraj Agarwal , Fred Saad , Arun Azad , Joaquin Mateo , Nobuaki Matsubara , Neal D. Shore , Jayeta Chakrabarti , Hsiang-Chun Chen , Silvana Lanzalone , Alexander Niyazov , Karim Fizazi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT04821622

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS5096)

DOI

10.1200/JCO.2022.40.16_suppl.TPS5096

Abstract #

TPS5096

Poster Bd #

277b

Abstract Disclosures

Similar Posters

First Author: Neeraj Agarwal

First Author: Neeraj Agarwal

First Author: Johann S. De Bono

First Author: Qiuxiang Ou